All sponsors

Allist Pharmaceuticals, Inc.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS12
PHASE 3 / 2-36
RECRUITING8
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO67%

Delay Index: of 12 active trials registered more than a year ago, 8 have moved their primary completion (readout) date by more than 6 months since first registration (median +14.8 months). See all sponsors →

Open Allist Pharmaceuticals, Inc. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Gefitinib 250 mg
NCT03787992
P3Active, not recruitingLocally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer3582021-09-15 (-20 mo)
JAB-21822
NCT05194995
P1/2Active, not recruitingAdvanced Colorectal Cancer; Small Intestinal Cancer482025-04-30 (+17 mo)
Furmonertinib
NCT05466149
P2Active, not recruitingNSCLC1002025-06-27 (+15 mo)
JAB-21822
NCT05009329
P1/2Active, not recruitingNSCLC; Solid Tumor3152026-08 (+8 mo)
FORWARD
NCT04853342
P3RecruitingNon-small Cell Lung Carcinoma3182026-12 (+36 mo)
JAB-21822
NCT06008288
P2RecruitingKRAS P.G12C; Pancreatic Cancer882026-12-31 (+20 mo)
JAB-21822
NCT05288205
P1/2RecruitingKRAS P.G12C; Non-small Cell Lung Cancer2402027-03 (+12 mo)
JAB 21822
NCT05276726
P1/2RecruitingNon-small Cell Lung Cancer1042027-08 (+44 mo)
Firmonertinib Mesilate Tablets
NCT06956001
P3RecruitingEGFR; NSCLC (Advanced Non-small Cell Lung Cancer)3002027-12
FIRMOST
NCT07010419
P3RecruitingNSCLC; Adjuvant Treatment3382028-10-31
Furmonertinib Mesilate Tablets
NCT06970639
P3RecruitingNSCLC Patients With Brain Metastasis3802029-03
JAB-21822
NCT06416410
P3RecruitingAdvanced Non-squamous Non-small-cell Lung Cancer; Metastatic Non-squamous Non Small Cell Lung Cancer3922029-09-30 (+36 mo)